Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Strubergasse 21, 5020, Salzburg, Austria.
Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University, Salzburg, Austria.
J Neuroinflammation. 2018 Sep 21;15(1):274. doi: 10.1186/s12974-018-1304-4.
Undoubtedly, neuroinflammation is a major contributor to Alzheimer's disease (AD) progression. Neuroinflammation is characterized by the activity of brain resident glial cells, in particular microglia, but also by peripheral immune cells, which infiltrate the brain at certain stages of disease progression. The specific role of microglia in shaping AD pathology is still controversially discussed. Moreover, a possible role of microglia in the interaction and recruitment of peripheral immune cells has so far been completely ignored.
We ablated microglia cells in 12-month-old WT and APP-PS1 transgenic mice for 4 weeks using the CSF1R inhibitor PLX5622 and analyzed its consequences to AD pathology and in particular to peripheral immune cell infiltration.
PLX5622 treatment successfully reduced microglia numbers. Interestingly, it uncovered a treatment-resistant macrophage population (Iba1/TMEM119). These cells strongly expressed the phagocytosis marker CD68 and the lymphocyte activation, homing, and adhesion molecule CD44, specifically at sites of amyloid-beta plaques in the brains of APP-PS1 mice. In consequence, ablation of microglia significantly raised the number of CD3/CD8 T-cells and reduced the expression of anti-inflammatory genes in the brains of APP-PS1 mice.
We conclude that in neurodegenerative conditions, chronically activated microglia might limit CD3/CD8 T-cell recruitment to the brain and that local macrophages connect innate with adaptive immune responses. Investigating the role of peripheral immune cells, their interaction with microglia, and understanding the link between innate and adaptive immune responses in the brain might be a future directive in treating AD pathology.
毫无疑问,神经炎症是阿尔茨海默病(AD)进展的主要原因。神经炎症的特征是脑固有神经胶质细胞(尤其是小胶质细胞)的活性,但也包括在疾病进展的某些阶段浸润大脑的外周免疫细胞。小胶质细胞在塑造 AD 病理学中的具体作用仍存在争议。此外,小胶质细胞在调节外周免疫细胞相互作用和募集方面的可能作用迄今已被完全忽略。
我们使用 CSF1R 抑制剂 PLX5622 在 12 月龄 WT 和 APP-PS1 转基因小鼠中消融小胶质细胞 4 周,并分析其对 AD 病理学的影响,特别是对外周免疫细胞浸润的影响。
PLX5622 治疗成功地减少了小胶质细胞的数量。有趣的是,它揭示了一种治疗抵抗的巨噬细胞群(Iba1/TMEM119)。这些细胞强烈表达吞噬作用标志物 CD68 和淋巴细胞激活、归巢和黏附分子 CD44,特别是在 APP-PS1 小鼠大脑中淀粉样β斑块的部位。因此,小胶质细胞的消融显著增加了 APP-PS1 小鼠大脑中 CD3/CD8 T 细胞的数量,并降低了大脑中抗炎基因的表达。
我们得出结论,在神经退行性疾病中,慢性激活的小胶质细胞可能限制 CD3/CD8 T 细胞向大脑的募集,而局部巨噬细胞将先天免疫与适应性免疫反应联系起来。研究外周免疫细胞的作用、它们与小胶质细胞的相互作用以及理解大脑中先天免疫与适应性免疫反应之间的联系,可能是治疗 AD 病理学的未来方向。